このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行性非小細胞肺がん(NSCLC)の参加者を対象とした選択された免疫療法の併用に関する第1b/2相プラットフォーム研究

2026年11月9日 更新者:Servier Bio-Innovation LLC

PD-L1高発現の未治療進行性非小細胞肺がん(NSCLC)の成人参加者を対象とした、選択された免疫療法の組み合わせに関する第1b/2相、多施設共同、非盲検プラットフォーム研究

This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.

調査の概要

研究の種類

介入

入学 (実際)

102

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Michigan
      • Detroit、Michigan、アメリカ、48202
        • Henry Ford Health
    • Ohio
      • Canton、Ohio、アメリカ、44718
        • Gabrail Cancer Center
      • Columbus、Ohio、アメリカ、43210
        • Ohio State University Comprehensive Cancer Center
      • London、イギリス、SW3 6JJ
        • The Royal Marsden in Chelsea
      • London、イギリス、SM2 5PT
        • The Royal Marsden in Sutton
      • Manchester、イギリス、M20 4BX
        • The Christie Nhs Foundation Foundation Trust
      • Aviano、イタリア、33081
        • Centro Di Riferimento Oncologico
      • Meldola、イタリア、47014
        • Inst. Romagnolo Per Lo Studio E La Cura Dei Tumori
      • Milan、イタリア、20162
        • ASST Grande Ospedale Metropolitano Niguarda
      • Milan、イタリア、20133
        • Irccs Fondazione Istituto Nazionale Dei Tumori
      • Milan、イタリア、20141
        • Istituto Europeo Di Oncologia
      • Naples、イタリア、80131
        • Ist. Nazionale Tumori Irccs Fondazione G Pascale
      • Perugia、イタリア、06132
        • Azienda Ospedaliera S. Maria Della Misericordia
      • Roma、イタリア、00144
        • Istituto Nazionale Tumori Regina Elena
      • Rozzano、イタリア、20089
        • Istituto Clinico Humanitas I.R.C.C.S
      • Albury、オーストラリア、2640
        • Border Medical Oncology Research Unit
      • Bedford Park、オーストラリア、5042
        • Flinders Medical Centre
      • St Albans、オーストラリア、3021
        • Sunshine Hospital
      • Traralgon、オーストラリア、3844
        • Latrobe Regional Health
      • Sankt Pölten、オーストリア、3100
        • Universitatsklinikum St. Poelten
      • Vienna、オーストリア、1090
        • Medical University of Vienna - Akh
      • Barcelona、スペイン、08035
        • Vall D' Hebron Institute of Oncology (Vhio), University Hospital
      • Madrid、スペイン、28007
        • Hospital General Universitario Gregorio Marañón
      • Madrid、スペイン、28027
        • Clinica Universitaria de Navarra (Madrid)
      • Madrid、スペイン、28050
        • Hospital Univ. Hm Sanchinarro Start Ciocc Early Phase
      • Málaga、スペイン、29010
        • Hospital Universitario Virgen de La Victoria
      • Valencia、スペイン、46026
        • Hospital Universitario Y Politecnico La Fe
      • Farkasgyepű、ハンガリー、8582
        • Farkasgyepu Tudogyogyintezet
      • Gyöngyös、ハンガリー、3200
        • Bugat Pal Hospital
      • Pécs、ハンガリー、7624
        • Pecsi Tudomanyegyetem, Klinikai Kozpont
      • Dijon、フランス、21079
        • Centre Georges Francois Leclerc
      • Grenoble、フランス、38043
        • Chu Grenoble Alpes
      • Marseille、フランス、13009
        • Institut Paoli Calmette
      • Saint-Herblain、フランス、44805
        • Centre René Gauducheau/Inst de Cancér. de L'Ouest
      • Villejuif、フランス、94805
        • Institut Gustave Roussy
      • Barretos、ブラジル、14784-400
        • Hospital de Amor - Barretos
      • Chapecó、ブラジル、89812618
        • Supera Oncologia
      • Curitiba、ブラジル、80810-050
        • CIONC
      • Natal、ブラジル、59035-055
        • Liga Contra O Cancer - Natal
      • Porto Alegre、ブラジル、90020-090
        • Santa Casa de Porto Alegre
      • Porto Alegre、ブラジル、90619-900
        • Hospital São Lucas Da Pucrs
      • Rio de Janeiro、ブラジル、22250-905
        • Oncoclinicas Rj
      • São Paulo、ブラジル、01509-010
        • Hospital A C Camargo
      • São Paulo、ブラジル、03102-002
        • Hospital São Camilo
      • São Paulo、ブラジル、04538-132
        • Oncoclinicas Sp
      • São Paulo、ブラジル、05652-900
        • Hospital Albert Einstein
      • Hasselt、ベルギー、3500
        • Jessa Ziekenhuis
      • Cluj-Napoca、ルーマニア
        • Inst Oncologic "Prof Dr I Chiricuta" Cluj Napoca
      • Taipei、台湾、100225
        • National Taiwan University Hospital
      • Taipei、台湾、114202
        • Tri-Service General Hospital
      • Hong Kong、香港
        • Queen Mary Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adult patient aged ≥ 18 years
  • Written informed consent
  • Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC
  • No prior systemic treatment for locally advanced or metastatic NSCLC
  • High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Measurable disease as determined by RECIST v1.1

Exclusion Criteria:

  • Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)
  • Prior immune checkpoint inhibitor therapy
  • Active brain metastases
  • Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll
  • Active, known or suspected autoimmune disease or immune deficiency
  • History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients
  • History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2
  • History of inflammatory bowel disease or colitis ≥ grade 2
  • History of hemophagocytic lymphohistiocytosis.
  • Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)
  • Clinically significant infection, as assessed by the investigator
  • Pregnant or breast-feeding (lactating) women
  • Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)
  • Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:S095018 (anti-TIM3 antibody) in combination with cemiplimab

Part A: Combination-therapy safety lead-in

Via IV infusion on Day 1 of each 21-day cycle

350 mg via IV infusion on Day 1 of each 21-day cycle

実験的:S095024 (anti-CD73 antibody) in combination with cemiplimab

Part A: Combination-therapy safety lead-in

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

実験的:S095029 (anti-NKG2A antibody) in combination with cemiplimab

Part A: Combination-therapy safety lead-in

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

実験的:S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

実験的:S095024 (anti-CD73 antibody) RDE in combination with cemiplimab

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

実験的:S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

アクティブコンパレータ:Cemiplimab (control arm)

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatment
時間枠:Through the end of the Cycle 2 (each cycle is 21 days)

Part A

Through the end of the Cycle 2 (each cycle is 21 days)
Incidence and severity of adverse events (AEs)
時間枠:From the signed informed consent form (ICF) to 30 days after the last dose

Part A

From the signed informed consent form (ICF) to 30 days after the last dose
Incidence and severity of serious adverse events (SAEs)
時間枠:From the signed ICF to 120 days after the last dose

Part A

From the signed ICF to 120 days after the last dose
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
時間枠:From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part A

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
時間枠:From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part A

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Objective Response (OR)
時間枠:Until study termination (approximately 2 years)

Part B: Participants who achieve complete response (CR) or partial response (PR), as per investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Until study termination (approximately 2 years)

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Response (OR)
時間枠:Until study termination (approximately 3 years)

Part A: Participants who achieve CR or PR, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
Best Overall Response (BOR)
時間枠:Until study termination (approximately 3 years)

Part A and B: The best response designation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST), recorded between the date of the first dose of treatment and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. CR or PR used in the BOR requires a confirmation that is at least 4 weeks apart.

Until study termination (approximately 3 years)
Duration of Response (DoR)
時間枠:Until study termination (approximately 3 years)

Part A and B: The time from the first documentation of CR or PR until the documented progressive disease (PD) or death, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
Disease Control (DC)
時間枠:Until study termination (approximately 3 years)

Part A and B: Participants who achieved stable disease (SD), PR, or CR (based on participant's best response), as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
6-month Durable Response (6-month DR)
時間枠:Until study termination (approximately 3 years)

Part A and B: Continuous CR or PR for ≥ 6 months, recorded between the date of the first dose of treatment and the date of the first objectively documented progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.

Until study termination (approximately 3 years)
Progression-Free Survival (PFS)
時間枠:Until study termination (approximately 3 years)

Part A and B: The time from the first dose to the first documented PD or death due to any cause, whichever occurs first, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
Plasma or serum concentration of S095018
時間枠:From first dose to 30 days after the last dose

Part A and B

From first dose to 30 days after the last dose
Plasma or serum concentration of S095024
時間枠:From first dose to 30 days after the last dose

Part A and B

From first dose to 30 days after the last dose
Plasma or serum concentration of S095029
時間枠:From first dose to 30 days after the last dose

Part A and B

From first dose to 30 days after the last dose
Incidence and titer of anti-drug antibodies (ADA) directed against S095018
時間枠:From screening to 90 days after the last dose

Part A and B

From screening to 90 days after the last dose
Incidence and titer of anti-drug antibodies (ADA) directed against S095024
時間枠:From screening to 90 days after the last dose

Part A and B

From screening to 90 days after the last dose
Incidence and titer of anti-drug antibodies (ADA) directed against S095029
時間枠:From screening to 90 days after the last dose

Part A and B

From screening to 90 days after the last dose
Incidence and severity of adverse events (AEs)
時間枠:From signed ICF to 30 days after the last dose

Part B

From signed ICF to 30 days after the last dose
Incidence and severity of serious adverse events (SAEs)
時間枠:From signed ICF to 120 days after the last dose

Part B

From signed ICF to 120 days after the last dose
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
時間枠:From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part B

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
時間枠:From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part B

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年8月7日

一次修了 (推定)

2027年4月1日

研究の完了 (推定)

2027年7月1日

試験登録日

最初に提出

2023年11月29日

QC基準を満たした最初の提出物

2023年12月7日

最初の投稿 (実際)

2023年12月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards
  • for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

IPD 共有時間枠

After Marketing Authorization in EEA or US if the study is used for the approval.

IPD 共有アクセス基準

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する